While Phase II-III studies include small datasets, comprising several hundred to several thousand patients, they provide the data necessary for drug approvals. The FDA approval of a drug is contingent on the drug company designing and implementing a post-marketing, or Phase IV study, designed to obtain additional data in a larger, real-world patient population. Join Dr. Keith Coffee as he explores how and why practicing physicians agree to participate in Phase IV studies. He will also address the common concerns many physicians raise regarding time spent and reimbursement for participating in these studies.
Explore related content and topics
Blog
Bridging Recruitment Gaps with Academic Collaboration
Blog
Beyond the First Step: What’s Next for COVID-19 Research
COVID-19 has sped up the process in terms of generating new kinds of vaccines and developing ways to gather real-world data. Read more about how this…
Case Study
Meeting Enrollment Goals Breast Cancer
An open-label, randomized, multi-center study to evaluate the use of Study Drug in the prevention of cancer treatment-related bone loss in…